Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 16, 2022 01:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe

Collaboration brings MyChoice CDx Plus Testing to Hamburg, Germany and Dijon, FranceLatest expansions represent Myriad’s commitment to growing international lab partner program SALT LAKE CITY, Aug....
August 16, 2022 01:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics kooperiert mit dem Institut für Hämopathologie Hamburg und dem Centre Georges-Francois LeClerc, um den Zugang zu Gentests in Europa zu erweitern

Zusammenarbeit bringt MyChoice CDx Plus Tests nach Hamburg, Deutschland und Dijon, FrankreichJüngste Erweiterungen zeigen untermauern Myriad’s Verpflichtung gegenüber einem wachsenden, internationalem...
August 16, 2022 01:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics s'associe à l'Institut für Hämopathologie Hamburg et au Centre Georges-François Leclerc pour étendre l'accès aux tests génétiques en Europe

Cette collaboration permet d’amener le test MyChoice CDx Plus à Hambourg en Allemagne et à Dijon en FranceL’expansion récente reflète l'engagement de Myriad à développer le programme international de...
August 04, 2022 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Second Quarter Financial Results

Highlights: Revenue of $179.3 million for the quarter ended June 30, 2022 Excluding revenue from divested businesses, revenue increased 7% year-over-year and 9% sequentially from the first quarter...
July 28, 2022 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022

SALT LAKE CITY, July 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second-quarter earnings conference call on...
July 19, 2022 17:07 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022

SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day on Aug. 11, 2022, providing a...
July 12, 2022 16:12 ET | Source: Myriad Genetics, Inc.

Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial

SALT LAKE CITY, July 12, 2022 (GLOBE NEWSWIRE) -- Major Depressive Disorder (MDD) remission rates were significantly improved when clinicians had access to GeneSight® Psychotropic test results from...
June 28, 2022 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

2021 report demonstrates focus on ESG initiatives supporting health equity, social justice, and sustainability SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:...
June 23, 2022 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration

Healthcare providers can easily order Myriad’s genetic tests for the more than 250 million patients within Epic’s networkPartnership bolsters Myriad’s growth plan to scale customer-centric,...
June 09, 2022 17:30 ET | Source: Myriad Genetics, Inc.

Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

SALT LAKE CITY, June 09, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the...